The present invention relates to the field of medical care, and it relates to the application of alkaloids and volatile oils contained in plants such as Gastrodia elata, Pinellia ternata, Orange Peel and Uncaria rhynchophylla in the preparation of medicines or health products for treating influenza or infectious diseases caused by viruses or fungi; especially, it relates to new use of the alkaloids and volatile oils contained in raw materials such as Gastrodia elata, Pinellia ternata, Orange Peel, Unearia and other plants in the preparation of drugs or health products for treating influenza or infectious diseases caused by influenza viruses (including HN avian influenza), coronavirus, Ebola virus, AIDS, Aspergillus, Cryptococcus, Mucor, Histoplasma capsulatum, etc.

The present invention relates to the field of medical care, and it relates to the application of alkaloids and volatile oils contained in plants such as Gastrodia elata, Pinellia ternata, Orange Peel and Uncaria rhynchophylla in the preparation of medicines or health products for treating influenza or infectious diseases caused by viruses or fungi; especially, it relates to new use of the alkaloids and volatile oils contained in raw materials such as Gastrodia elata, Pinellia ternata, Orange Peel, Unearia and other plants in the preparation of drugs or health products for treating influenza or infectious diseases caused by influenza viruses (including HN avian influenza), coronavirus, Ebola virus, AIDS, Aspergillus, Cryptococcus, Mucor, Histoplasma capsulatum, etc.

The present invention relates to the field of medical care, and it relates to the application of alkaloids and volatile oils contained in plants such as Gastrodia elata, Pinellia ternata, Orange Peel and Uncaria rhynchophylla in the preparation of medicines or health products for treating influenza or infectious diseases caused by viruses or fungi; especially, it relates to new use of the alkaloids and volatile oils contained in raw materials such as Gastrodia elata, Pinellia ternata, Orange Peel, Unearia and other plants in the preparation of drugs or health products for treating influenza or infectious diseases caused by influenza viruses (including HN avian influenza), coronavirus, Ebola virus, AIDS, Aspergillus, Cryptococcus, Mucor, Histoplasma capsulatum, etc.

The object of the invention is topical compositions comprising pea proteins and polyphenols and the use thereof for the treatment of local or generalised disorders caused by increased permeation of the natural epithelial barriers. Said disorders may be of bacterial, viral, inflammatory, allergic and/or fungal origin, or endogenous or idiopathic.

The object of the invention is topical compositions comprising pea proteins and polyphenols and the use thereof for the treatment of local or generalised disorders caused by increased permeation of the natural epithelial barriers. Said disorders may be of bacterial, viral, inflammatory, allergic and/or fungal origin, or endogenous or idiopathic.

A biochemical scaffold for regulating mammalian cell function. The biochemical scaffold includes a base liquid medium, a bioenergetic platform and a vibrational platform. The bioenergetic platform includes at least one Krebs cycle modulator and the vibrational platform includes at least one energy signature component, e.g., an herb. The biochemical scaffold is subjected to sequential harmonic oscillation at defined frequency ranges for a defined, predetermined period of time, wherein the energy signature of the energy signature component is imparted to, captured, replicated, and retained by liquid medium, and, when the biochemical scaffold is delivered to and, thus, in communication with biological tissue, the biochemical scaffold induces specific biochemical activities via the resonant transfer of the retained energy signature to the biological tissue and, hence, endogenous cells thereof, the biochemical activities including increased bioavailability of ATP.

A biochemical scaffold for regulating mammalian cell function. The biochemical scaffold includes a base liquid medium, a bioenergetic platform and a vibrational platform. The bioenergetic platform includes at least one Krebs cycle modulator and the vibrational platform includes at least one energy signature component, e.g., an herb. The biochemical scaffold is subjected to sequential harmonic oscillation at defined frequency ranges for a defined, predetermined period of time, wherein the energy signature of the energy signature component is imparted to, captured, replicated, and retained by liquid medium, and, when the biochemical scaffold is delivered to and, thus, in communication with biological tissue, the biochemical scaffold induces specific biochemical activities via the resonant transfer of the retained energy signature to the biological tissue and, hence, endogenous cells thereof, the biochemical activities including increased bioavailability of ATP.

A biochemical scaffold for regulating mammalian cell function. The biochemical scaffold includes a base liquid medium, a bioenergetic platform and a vibrational platform. The bioenergetic platform includes at least one Krebs cycle modulator and the vibrational platform includes at least one energy signature component, e.g., an herb. The biochemical scaffold is subjected to sequential harmonic oscillation at defined frequency ranges for a defined, predetermined period of time, wherein the energy signature of the energy signature component is imparted to, captured, replicated, and retained by liquid medium, and, when the biochemical scaffold is delivered to and, thus, in communication with biological tissue, the biochemical scaffold induces specific biochemical activities via the resonant transfer of the retained energy signature to the biological tissue and, hence, endogenous cells thereof, the biochemical activities including increased bioavailability of ATP.

The embodiments of the present disclosure generally relate to a formulation for alleviating veisalgia symptoms. The formulation can comprise anhydrous caffeine, salicin, and valerian. The components can be delivered within a liquid medium and act synergistically to more effectively relieve veisalgia symptoms than when taken individually.

The embodiments of the present disclosure generally relate to a formulation for alleviating veisalgia symptoms. The formulation can comprise anhydrous caffeine, salicin, and valerian. The components can be delivered within a liquid medium and act synergistically to more effectively relieve veisalgia symptoms than when taken individually.